LLY Eli Lilly and Co.
Yhden AI-mallin esikatselu (DeepSeek): Eli Lilly and Co., arvio $809.90 vs markkinahinta $1188.58 (-31.9%). Analyytikkoseuranta: 28. Kokeellista tutkimusta — ei sijoitusneuvontaa.
Yhtiöstä
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for
Mallin oletukset (DeepSeek)
Viikkohistoria
| Päivä | Spot | Esikatseluarvio | Gap |
|---|---|---|---|
| 2026-07-11 | $1188.58 | $809.90 | -31.9% |
| 2026-07-04 | $1213.91 | $837.89 | -31.0% |
| 2026-07-03 | $1213.91 | $837.89 | -31.0% |
| 2026-07-02 | $1213.91 | $850.81 | -29.9% |